Rizatriptan Benzoate Tablet
Product Images NDC 71335-1912

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 71335-1912). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (Lbl713351912)

Label (Lbl713351912)
This appears to be a label of a medication called "Rizatriptan". It comes in a pink, round tablet form with a strength of 10mg as a blister pack. The recommended storage temperature is 20°-25°C (68°-77°F) at room temperature. The label also provides details such as its National Drug Code (NDC) number of 7133519121 and an expiration date. Patients are advised to store it in a safe place out of reach of children.*
FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)
Figure 1 displays the probability of achieving an initial headache response in a pooled study of four placebo-controlled outpatient trials using Rizatriptan Benzoate. The graph shows estimated probabilities in percentages ranging from 100% to 0% on the Y-axis at various hours post-dose on the X-axis. The different estimated response rates are based on the dosage of the medication. The averages were obtained by pooling data from the four trials. The Kaplan-Meier plot is used to show the rate of obtaining headache response (no or mild pain) with Rizatriptan Benzoate or placebo over time. The study only included patients who responded to treatment within two hours.*
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)
The Figure 2 graph shows the percentage of patients who took a second dose of Rizatriptan Benzoate tablets or other medication for migraines over a 24 hour period following the initial dose. The data displayed was obtained from four placebo-controlled outpatient clinical studies, and includes both patients who had a headache response at 2 hours and those who did not. Remedication was not allowed within 2 hours of the initial dose.*
FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig3)

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig3)
The text represents a graph or chart labeled "Figure5" that shows the percentage (with a 95% confidence interval) of patients reporting no headache pain by 2 hours after taking medication. The observed percentage is plotted for both Rizatriptan Benzoate Orally Disintegrating Tablets and placebo. The x-axis extends up to 20 hours after the stage 2 dose, with data points plotted at 5-hour intervals.*
FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical Structure (Rizatriptan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.